Skip to main content

Table 3 Unadjusted and adjusted hazard ratios of the impact of MMR immunophenotype on overall survival in I-type tumors, PB-type tumors, and the entire cohort

From: Relationship between mismatch repair immunophenotype and long-term survival in patients with resected periampullary adenocarcinoma

  Intestinal type Pancreatobiliary type All
n (events) Unadjusted Adjusted n (events) Unadjusted Adjusted n (events) Unadjusted Adjusted
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Age
 Continuous 63 (39) 1.01 (0.98–1.05) 109 (98) 0.99 (0.97–1.02) 172 (137) 1.01 (0.99–1.03)
Gender
 Female 35 (17) 1.00 1.00 51 (45) 1.00 86 (62) 1.00
34 (16)*
 Male 28 (22) 2.01 (1.05–3.84) 1.60 (0.79–3.24) 58 (53) 1.15 (0.77–1.71)   86 (75) 1.40 (1.00–1.97)  
  27 (21)*         
Tumor origin
 Intestinal    63 (39) 1.00 1.00
        61 (37)*   
 Pancreatobiliary type    109 (98) 2.54 (1.73–3.73) 1.61 (1.01–2.55)
        108 (98)*   
Tumor size
 Continuous 63 (39) 1.00 (0.98–1.02) 109 (98) 1.04 (1.02–1.06) 1.02 (1.00–1.04) 172 (137) 1.02 (1.00–1.03) 1.01 (0.99–2.55)
     108 (98)*    169 (135)*   
T-stage
 T1–T2 16 (8) 1.00 15 (10) 1.00 1.00 31 (18) 1.00 1.00
     14 (10)*    28 (16)*   
 T3–T4 47 (31) 1.72 (0.79–3.74)   94 (88) 2.47 (1.28–4.77) 1.06 (0.50–2.27) 141 (119) 2.34 (1.42–3.86) 1.21 (0.66–2.21)
     94 (88)*    141 (119)*   
N-stage
 N0 35 (19) 1.00 32 (25) 1.00 1.00 67 (44) 1.00 1.00
     31 (25)*    64 (42)*   
 N1–2 28 (20) 1.56 (0.83–2.94)   77 (73) 2.23 (1.41–3.54) 2.06 (1.16–3.65) 105 (93) 2.19 (1.52–3.16) 1.34 (0.88–2.05)
     77 (73)*    105 (93)*   
Differentiation grade
 Well-moderate 31 (17) 1.00 42 (32) 1.00 1.00 73 (49) 1.00 1.00
     41 (32)*    71 (48)*   
 Poor 32 (22) 1.70 (0.90–3.21)   67 (66) 2.63 (1.70–4.09) 2.05 (1.24–3.39) 99 (88) 2.24 (1.57–3.18) 1.65 (1.09–2.48)
     67 (66)*    98 (87)*   
Involved margins, status
 R0 18 (5) 1.00 1.00 7 (5) 1.00 25 (10) 1.00 1.00
  17 (4)*       23 (9)*   
 R1 and Rx 45 (34) 3.30 (1.29–8.46) 2.89 (0.94–8.85) 102 (93) 2.42 (0.98–6.00)   147 (127) 3.57 (1.87–6.83) 2.23 (1.10–4.51)
  44 (33)*       146 (126)*   
Lymphatic growth
 Absent 28 (10) 1.00 1.00 35 (27) 1.00 1.00 63 (37) 1.00 1.00
  28 (10)*    34 (27)*    62 (37)*   
 Present 35 (29) 3.94 (1.90–8.18) 1.77 (0.77–4.09) 74 (71) 1.78 (1.13–2.79) 1.09 (0.65–1.83) 109 (100) 2.54 (1.73–3.73) 1.33 (0.85–2.07)
  33 (27)*    74 (71)*    107 (98)*   
Vascular growth
 Absent 58 (34) 1.00 1.00 73 (62) 1.00 1.00 131 (96) 1.00 1.00
  56 (32)*    72 (62)*    128 (94)*   
 Present 5 (5) 6.68 (2.40–18.62) 4.69 (1.48–14.84) 36 (36) 2.47 (1.61–3.80) 2.20 (1.38–3.52) 41 (41) 3.49 (2.37–5.15) 2.18 (1.43–3.34)
  5 (5)*    36 (36)*    41 (41)*   
Perineural growth
 Absent 43 (21) 1.00 1.00 25 (19) 1.00 1.00 68 (40) 1.00 1.00
  42 (20)*    24 (19)*    66 (39)*   
 Present 20 (18) 2.81 (1.48–5.35) 1.36 (0.57–3.21) 84 (79) 1.96 (1.18–3.25) 0.88 (0.48–1.61) 104 (97) 2.96 (2.02–4.43) 1.06 (0.66–1.71)
  19 (17)*    84 (79)*    103 (96)*   
Growth in peripancreatic fat
 Absent 42 (20) 1.00 1.00 25 (20) 1.00 1.00 67 (40) 1.00 1.00
  40 (18)*    24 (20)*    64 (38)*   
 Present 21 (19) 3.65 (1.86–7.16) 1.78 (0.73–4.33) 84 (78) 1.75 (1.06–2.88) 0.99 (0.56–1.77) 105 (97) 3.00 (2.03–4.43) 1.37 (0.85–2.22)
  21 (19)*    84 (78)*    105 (97)*   
Adjuvant treatment
 None 45 (30) 1.00 50 (44) 1.00 95 (74) 1.00
 Any 18 (9) 0.69 (0.33–1.47)   59 (54) 0.96 (0.64–1.42)   77 (63) 1.09 (0.78–1–53)  
MMR
 pMMR 49 (34) 1.00 1.00 101 (93) 1.00 1.00 150 (127) 1.00 1.00
  49 (34)*    101 (93)*    150 (127)*   
 dMMR 12 (3) 0.20 (0.06–0.68) 0.36 (0.09–1.42) 7 (5) 0.57 (0.23–1.42) 1.24 (0.46–3.37) 19 (8) 0.28 (0.13–0.57) 0.52 (0.23–1.19)
  12 (3)*    7 (5)*    19 (8)*   
  1. Italic values indicate significance at p < 0.05
  2. *Number and events for the adjusted analysis
\